Merck, Roche unveil new moves for Africa growth; AbbVie, Lundbeck tout new study results;

> Merck KGaA teamed up with African healthcare providers and lawmakers for "More than a Mother," a campaign to train doctors about fertility problems and treatments, improve access to care in the field, and boost awareness among women about their options. Release

> Novo Nordisk ($NVO) won laurels for its green strategies and workplace environment, with Newsweek placing it in 15th place for corporate sustainability worldwide and Fortune naming it one of the best 100 companies for millennial employees. More | Release

> AbbVie ($ABBV) rolled out new data showing its hepatitis C drug cocktail showed a 100% cure rate in genotype 1b patients with cirrhosis, as it works to gain ground in the competitive field. Release

> Lundbeck said a new data analysis showed its long-lasting antipsychotic injection Abilify Maintena beat head-to-head rival Invega Sustenna at improving functioning and quality of life in young people with schizophrenia. Release

> In early guidance, England's cost-effectiveness watchdogs rejected Santen Pharmaceutical's Ikervis (ciclosporin) as a treatment for keratitis in dry eye patients. Report

And Finally... Roche ($RHHBY) said it is rolling out a new strategy for Africa, aiming to increase access to its drugs, first in 7 targeted countries. Report

Suggested Articles

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.

To take on AbbVie’s megablockbuster Humira, drugmakers need compelling data for physicians. Could Eli Lilly's Taltz be up to the challenge?

Why did GSK tweak its strict ethics measures for sales reps? When it first nixed incentive-based compensation, it thought other pharmas would, too.